Screener
Amneal Pharmaceuticals, Inc. AMRX Specialty — Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other therapeutic classes | 11,852 | 8,700 | 25,802 | 15,188 |
| Subtotal therapeutic classes | 149,295 | 127,543 | 282,560 | 235,840 |
| License agreement | — | 500 | — | 500 |
| Total Specialty net revenue | 149,295 | 128,043 | 282,560 | 236,340 |
| AvKARE | ||||
| Distribution | 86,930 | 99,663 | 176,079 | 204,558 |
| Government label | 50,207 | 45,418 | 110,156 | 95,558 |
| Institutional | 12,112 | 10,132 | 21,931 | 21,141 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s specialty — revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — revenue of $149.3M in Q2 2026.
- How has Amneal Pharmaceuticals, Inc.'s specialty — revenue changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s specialty — revenue increased by 16.6% year-over-year, from $128.04M to $149.3M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s specialty — revenue?
- Over 4 years (2021 to 2025), Amneal Pharmaceuticals, Inc.'s specialty — revenue has grown at a 8.7% compound annual growth rate (CAGR), from $378.32M to $528.51M.
- What does specialty — revenue mean?
- Represents the total gross revenue generated from the sale of specialty pharmaceutical products to customers, net of any sales-related taxes. This is the primary top-line performance indicator for the specialty segment, reflecting market demand and pricing power for proprietary branded medicines. It is essential for evaluating the segment's growth trajectory and market penetration.
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude